Bioventus Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Bioventus Inc 's ROA in the second quarter of 2026?
Bioventus Inc achieved a return on average assets (ROA) of 9.09 % in its second quarter of 2026, this is above BVS's average return on assets of -7.37%.
Bioventus Inc assets over the 12 months ending in its second quarter of 2026 are valued at $676 million

ROA has improved compared to 5.04% in the first quarter of 2026, due to net income growth.

However, within the Healthcare sector 103 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 27 2026 quarter, so far to 1167, from total ROA ranking in the first quarter of 2026 at 1618.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 27 2026) II. Quarter	(Mar 28 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 27 2025) III. Quarter	(Jun 28 2025) II. Quarter
Y / Y Total Assets Change	-4.73 %	-4.49 %	-5.23 %	-8.18 %	-9.15 %
Y / Y Net Income Change	290.48 %	-	-	-	-
Net Income (TTM) in million	61	35	27	10	0
Return On Assets (TTM)	9.09 %	5.04 %	3.94 %	1.4 %	0.05 %
BVS's Total Ranking	# 1167	# 1618	# 2033	# 2544	# 3040
Total Assets (TTM) in million	673	653	686	694	707
Seq. Total Assets Change	3.17 %	-4.84 %	-1.18 %	-1.8 %	3.44 %
Seq. Net Income Change	817.51 %	-77.21 %	332.3 %	-56.79 %	-

BVS's 5 Years Annual ROA >> Back to BVS Management Effectiveness >> Compare BVS ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 31
Sector	# 104
Overall	# 667

Return On Assets Statistics
High	Average	Low
9.08 %	-7.37 %	-32.9 %
(Jun 27 2026)		(Jul 01 2023)

Financial Statements
Bioventus Inc 's Assets	$ 673 million	BVS's Balance sheet
Bioventus Inc 's Income	$ 36 million	Quarterly BVS's Income Statement
BVS's Income by Division		See BVS's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-5.23 %	-9.42 %	-41.15 %	12.19 %	-
Total Assets in million	686	724	799	1,358	1,210
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	27	-44	-196	-213	10
Annual Return On Assets	3.98 %	-6.06 %	-24.49 %	-15.72 %	0.79 %

BVS's 5 Years Annual ROA >> Back to BVS Management Effectiveness >> Compare BVS ROA to its Competitors

Comment on BVS's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 3.98 % compared to prior year, due to annual net income growth of % to $27.27 million, and due to decline of value in Bioventus Inc 's assets by -5.23 % to $685.85 million, compared to $685.85 a year before.

More Return On Assets Ratios
BVS's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
BVS's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for BVS's Competitors
Subscribers only: Roa for Bioventus Inc 's Suppliers
Subscribers only: Return On Assets for BVS's Customers

You may also want to know
BVS's Roi	BVS's Inventory Turnover Ratio	BVS's Growth Rates	BVS's Dividend Comparisons
	BVS's Profitability Ratios	BVS's Asset Turnover Ratio	BVS's Dividend Growth
BVS's Roe	BVS's Valuation Ratios	BVS's Financial Strength Ratios	BVS's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 27 2026, within Healthcare Sector	ROA
Mettler toledo International Inc	24.86 %
Medpace Holdings Inc	24.84 %
Caredx Inc	24.81 %
Acadia Pharmaceuticals Inc	24.38 %
Eli Lilly And Company	21.97 %
Innoviva Inc	21.64 %
Vaxart Inc	20.85 %
Zevra Therapeutics Inc	20.39 %
Iradimed Corporation	20.36 %
Protalix Biotherapeutics inc	20.09 %
Pro dex Inc	19.87 %
Electromed Inc	19.39 %
United Therapeutics Corporation	17.98 %
Resmed Inc	17.80 %
Krystal Biotech Inc	17.65 %
Chemed Corporation	17.52 %
Zoetis Inc	17.19 %
Vertex Pharmaceuticals Inc	16.88 %
Halozyme Therapeutics Inc	16.55 %
Alnylam Pharmaceuticals Inc	15.76 %
Intuitive Surgical Inc	15.63 %
Healthcare Services Group Inc	15.21 %
Inspire Medical Systems inc	15.21 %
Dexcom Inc	14.87 %
Neurocrine Biosciences Inc	14.73 %
Entera Bio Ltd	14.60 %
Standard Biotools Inc	14.31 %
Arcutis Biotherapeutics Inc	14.23 %
Harmony Biosciences Holdings inc	14.15 %
Biolife Solutions Inc	14.09 %

Date modified: 2026-09-09T22:40:19+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.